{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:10:00Z","timestamp":1792091400078,"version":"4.4.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Mineralocorticoid receptor over-activation drives maladaptive myocardial fibrosis, vascular inflammation and renal sodium retention across the entire spectrum of left ventricular ejection fraction (LVEF). While steroidal MRAs have convincingly reduced hospitalizations and mortality in patients with heart failure and reduced EF (HFrEF), evidence remains fragmented for heart failure with mildly reduced (HFmrEF) or preserved EF (HFpEF), and no head-to-head data distinguish steroidal from non-steroidal agents. This study aimed to evaluate the effect of MRAs in patients with HF across the range of ejection fraction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Searched PubMed, Web of Science, Wanfang and Cochrane library (1 Jan 1987\u201310 Sep 2024) for randomized clinical trials (RCT) assessing MRAs (finerenone, spironolactone, eplerenone) in HFpEF, HFmrEF or HF. The primary endpoint was composite cardiovascular (CV) outcomes. Secondary endpoints included CV mortality, overall HF exacerbation events, safety, and adverse events. A meta-analysis was conducted using hazard ratios (HR), confidence intervals (CI), and relative risks (RR) to synthesize the findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the analysis of nine RCTs, MRAs were associated with a 23% reduction in CV composite outcomes (RR: 0.77, 95% CI: 0.72\u20130.83, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.00001), a 23% reduction in HF hospitalization risk (HR: 0.77, 95% CI: 0.70\u20130.84, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.00001), and a 22% reduction in all-cause mortality (HR: 0.78, 95% CI: 0.72\u20130.85, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.00001) in HFrEF patients, compared to a 17% reduction in CV composite events (HR: 0.85, 95% CI: 0.78\u20130.93, <jats:italic>P<\/jats:italic>\u2009=\u20090.0004), a 20% reduction in HF hospitalization risk (HR: 0.80, 95% CI: 0.73\u20130.89, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.00001), and an 8% reduction in all-cause mortality (HR: 0.91, 95% CI: 0.85\u20130.99, <jats:italic>P<\/jats:italic>\u2009=\u20090.02) in HFmrEF\/HFpEF patients. However, CV mortality was not significantly reduced in HFmrEF\/HFpEF patients (HR: 0.92, 95% CI: 0.82\u20131.02, <jats:italic>P<\/jats:italic>\u2009=\u20090.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70\u20130.83, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.00001). The incidence of any serious adverse events was similar between the MRA and placebo groups. The incidence of hyperkalemia was significantly higher in the MRA group (RR: 2.19, 95% CI: 1.97\u20132.43, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.00001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>MRAs should be considered for patients with HFrEF due to their substantial benefits. In HFmrEF or HFpEF, MRAs may confer benefit, though the effect is modest and hyperkalemia risk is higher, mandating close potassium monitoring.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>PROSPERO CRD42022304966.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1667236","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T05:30:54Z","timestamp":1756704654000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Yue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Chao","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei-Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin-Yan","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ze","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 Esc guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the heart failure association (hfa) of the esc","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e011629","DOI":"10.1161\/CIRCHEARTFAILURE.124.011629","article-title":"Mineralocorticoid receptor antagonists in heart failure: an update","volume":"17","author":"Ferreira","year":"2024","journal-title":"Circ Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10741-019-09790-5","article-title":"Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials","volume":"24","author":"Yang","year":"2019","journal-title":"Heart Fail Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"w13959","DOI":"10.4414\/smw.2014.13959","article-title":"Heart failure: the role for mineralocorticoid receptor antagonists","volume":"144","author":"Pitt","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1253\/circj.CJ-25-0002","article-title":"JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure","volume":"89","author":"Kitai","year":"2025","journal-title":"Circ J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.amjcard.2019.11.014","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists in patients with heart failure and chronic kidney disease","volume":"125","author":"Khan","year":"2020","journal-title":"Am J Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10741-019-09832-y","article-title":"Relative efficacy of spironolactone, eplerenone, and canrenone in patients with chronic heart failure (research): a systematic review and network meta-analysis of randomized controlled trials","volume":"25","author":"Frankenstein","year":"2020","journal-title":"Heart Fail Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/j.jacc.2024.03.426","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function","volume":"83","author":"Matsumoto","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the heart failure society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and writing committee of the universal definition of heart failure: endorsed by the Canadian Heart Failure Society, heart failure association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B13","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the aldo-dhf randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist bay 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jchf.2021.05.009","article-title":"Advanced heart failure epidemiology and outcomes: a population-based study","volume":"9","author":"Dunlay","year":"2021","journal-title":"JACC Heart Fail"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"Focused update of the 2021 esc guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"2023","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.3390\/ijms25063113","article-title":"Beyond quadruple therapy and current therapeutic strategies in heart failure with reduced ejection fraction: medical therapies with potential to become part of the therapeutic armamentarium","volume":"25","author":"Kourek","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1113\/JP280691","article-title":"A horse of a different colour: distinct mechanisms of hfpef and hfref","volume":"598","author":"Louch","year":"2020","journal-title":"J Physiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e027984","DOI":"10.1136\/bmjopen-2018-027984","article-title":"Heart failure with preserved ejection fraction (hfpef) pathophysiology study (identify-hf): does increased arterial stiffness associate with hfpef, in addition to ageing and vascular effects of comorbidities? Rationale and design","volume":"9","author":"Ali","year":"2019","journal-title":"BMJ Open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/HJH.0000000000003643","article-title":"Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit?","volume":"42","author":"Huang","year":"2024","journal-title":"J Hypertens"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"Esh guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ish) and the European renal association (era)","volume":"2023","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"Esc guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"2021","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure: jacc state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"9995","DOI":"10.3390\/ijms22189995","article-title":"Mineralocorticoid receptor antagonists-use in chronic kidney disease","volume":"22","author":"Baran","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/ndt\/gfac284","article-title":"Steroidal or non-steroidal mras: should we still enable raasi use through k binders?","volume":"38","author":"Gregg","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/ajhp\/zxad192","article-title":"Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes","volume":"80","author":"Ashjian","year":"2023","journal-title":"Am J Health Syst Pharm"},{"key":"B40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2478\/jtim-2023-0114","article-title":"Cardiac magnetic resonance imaging-derived septum swing index detects pulmonary hypertension: a diagnostic study","volume":"11","author":"He","year":"2023","journal-title":"J Transl Int Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1667236\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T05:30:55Z","timestamp":1756704655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1667236\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":40,"alternative-id":["10.3389\/fcvm.2025.1667236"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1667236","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"article-number":"1667236"}}